bioRxiv (Cold Spring Harbor Laboratory)
July 20, 2026
Neil K. Savalia, Ling-Xiao Shao, Cory A. Knox et al.
SUMMARY How psychedelics act on cortical dendrites to produce long-lasting structural plasticity remains poorly understood. Here, we characterize the effects of psilocybin on dendritic calcium dynamics in pyramidal tract neurons of the mouse medial frontal cortex. Psilocybin transiently increases calcium event rates in apical dendritic tufts over a time course that parallels the drug’s...
Neuropsychopharmacology
July 18, 2026
James J Gattuso, Ahmed Kamal, Jennyfer M. Payet et al.
Abstract Psilocybin is a serotonergic psychedelic drug with emerging therapeutic applications, yet its actions under glutamatergic dysfunction, and relevance to schizophrenia and associated psychiatric disorders, remain unclear. We examined the acute and long-lasting effects of psilocybin (1 mg/kg, intraperitoneal) on behavioral and neural outcomes in the metabotropic glutamate receptor 5...
Zenodo (CERN European Organization for Nuclear Research)
July 17, 2026
Bartosz Niciński, Magdalena Kloc, Ewa Wiench, Natasza Millan, Aleksandra Blicharz, Wojciech Kozdraś, Lidia Kozaczko, Gabriela Szewczyk, Elżbieta Bukowczan, Alicja Zając, Damian Broda, Alicja Benecka
Major depressive disorder is a highly burdensome psychiatric condition worldwide, and many patients do not achieve full remission after standard monoaminergic antidepressant treatment. This has contributed to growing interest in rapid-acting antidepressant interventionstargeting neurobiological pathways beyond traditional serotonin, norepinephrine, and dopamine mechanisms. This review...
Molecular Psychiatry
July 16, 2026
Marco Taddei-Tardón, Lidia Medina-Rodríguez, Jessica L Maltman et al.
Serotonergic psychedelics have attracted considerable interest as promising therapeutic agents. However, the molecular mechanisms linking their acute hallucinogenic-like effects to longer-lasting neuroplastic responses remain incompletely understood, partly because of the scarcity of native neural models suitable for mechanistic studies. Here, we developed a neural stem cell-derived in vitro...
Frontiers in Psychiatry
July 15, 2026
Rafał Marecki, Wiktoria Zaniewska, Adam Hamed et al.
Classic psychedelics, including psilocybin, LSD, DMT, 5-MeO-DMT, mescaline, and phenethylamines such as DOI, exert their core effects through 5-HT2A receptor agonism, inducing widespread neurobiological and behavioral changes relevant to psychiatric research. Emerging evidence suggests that these effects are modulated by sex, yet this dimension remains underrepresented in studies. This review...
British Journal of Pharmacology
July 14, 2026
Darta Stalberga, Robert Kronstrand, Bianca Schranz et al.
New psychoactive substances (NPSs) often emerge on the illicit drug market with limited pharmacological or toxicological data. Synthetic cathinones are the second largest NPS group, often mimicking the effects of classical stimulants such as cocaine and methylenedioxymethamphetamine (MDMA). Such stimulants primarily target dopamine (DAT), norepinephrine (NET) and serotonin (SERT) transporters,...
July 10, 2026
Lohani Noor
A resurgent therapeutic frontier, the contemporary renaissance in psychedelic science has accelerated investigation of classic serotonergic psychedelics (psilocybin, lysergic acid diethylamide (LSD), N,N-dimethyltryptamine (DMT), mescaline), empathogenic entactogenic agents (3,4-methylenedioxymethamphetamine (MDMA)), and glutamatergic dissociatives (ketamine) as adjuncts to psychotherapy. While...
ACS Medicinal Chemistry Letters
July 10, 2026
Anna C. Renner, Robert B. Kargbo
High Resolution Image Download MS PowerPoint Slide The psychedelic therapeutics field continues to evolve beyond classical hallucinogens toward integrated treatment platforms that combine optimized pharmacology, drug delivery, and clinical implementation. Recent patent applications disclose selective 5-HT2A receptor activators, precision aerosol delivery technologies for psychedelic compounds,...
European Journal of Pharmacology
July 10, 2026
Amanda Gollo Bertollo, Vinicius Alexandre Wippel, Maiqueli Eduarda Dama Mingoti et al.
Major Depressive Disorder (MDD) is a debilitating mental health condition that significantly impacts quality of life. Despite available pharmacological treatments, response rates remain suboptimal, with a considerable number of patients experiencing treatment-resistant depression (TRD). Indeed, classical antidepressants, primarily targeting monoaminergic systems, exhibit a therapeutic delay due...
Pharmacology Biochemistry and Behavior
July 9, 2026
Sofía Villalba, Agustín Martínez Christensen, Lucia di Costanzo et al.
In recent years, psychedelics have shown promising results as therapeutic interventions for individuals with depression, terminal illnesses, substance use disorder, neurodegenerative diseases, trauma and obsessive-compulsive disorder. Moreover, research involving psychedelics have contributed to the understanding of the neurobiological mechanisms behind the "psychedelic state of consciousness"...
Open Science Framework
July 9, 2026
Raul Edison Luna Lazo, Nicole Milagritos Cardoso Azorza, Jatziri Yanina Vilca Yanac et al.
Obsessive-compulsive disorder (OCD) is a chronic neuropsychiatric condition characterized by intrusive thoughts and repetitive behaviors that cause distress and functional impairment worldwide. Although selective serotonin reuptake inhibitors and cognitive behavioral therapy are first-line treatments, a considerable proportion of patients show an insufficient response, supporting the need for...
Molecular Psychiatry
July 8, 2026
Granville J. Matheson, Johan Lundberg, Martin Gärde et al.
The serotonin 1B receptor can be studied in vivo with PET using [^11C]AZ10419369, and has been linked to both the pathophysiology and treatment of major depressive disorder (MDD). Ketamine and electroconvulsive therapy (ECT) both exert rapid and potent antidepressive effects, and although these treatments may not act directly on the serotonin system, they both cause dose-dependent increases in...
Zenodo (CERN European Organization for Nuclear Research)
July 7, 2026
There is limited or indirect evidence suggesting that combined use of MDMA and SSRIs may increase the risk of serotonin syndrome. Healthcare providers should be vigilant in identifying symptoms and discourage such drug interactions.
Mol Psychiatry
July 7, 2026
Axel F. Rosado, Abigail L. Yu, Jen-Hau Yang et al.
Classic serotonergic psychedelics such as psilocybin act as agonists at cortical serotonin (5-HT) 2A receptors (5-HT 2A R), inducing psychedelic effects in humans and head-twitch responses (HTRs) in rodents. Another class of psychedelic drugs called entactogens, exemplified by MDMA, function primarily as monoamine releasers and typically evoke minimal HTR despite causing serotonin release. The...
Biomedicines
July 6, 2026
Kasper Buczma, Katarzyna Kamińska, Kaja Kasarełło et al.
Background/Objectives: Psilocibin (PSY), a serotonergic hallucinogen, has attracted increasing scientific interest due to its therapeutic potential, particularly in treatment-resistant depression. In parallel with its growing clinical and research relevance, important questions have emerged regarding its safety profile, including potential effects on the liver, kidneys, cardiovascular system,...
Mexican Journal of Medical Research ICSA
July 5, 2026
Omar Azuara-Antonio, Erika Rubí de la Cruz-Elizaldeb, José Eduardo Carmona-Rodriguez et al.
The Psilocybe cubensis mushroom is recognized as the primary source of psilocybin in the Americas, occurring naturally across various regions. This fungus has a long history of use in Mesoamerican rituals due to its capacity to induce altered states of consciousness. The defining characteristic of Psilocybe mushrooms is their psilocybin content. Following ingestion, psilocybin is metabolized...
ACS Medicinal Chemistry Letters
July 3, 2026
Ram W. Sabnis, Anika R. Sabnis
High Resolution Image Download MS PowerPoint Slide Provided herein are novel 6,5-bicyclic compounds as 5-HT2A receptor agonists, pharmaceutical compositions, use of such compounds in treating depression, anxiety, substance abuse, and headaches, and processes for preparing such compounds.
bioRxiv (Cold Spring Harbor Laboratory)
July 3, 2026
Anastasia Tyulmenkova, Robert W. Stackman
Abstract Serotonin (5-HT) 2A receptors (5-HT 2 AR) modulate corticolimbic circuits regulating fear extinction. Although activation of these receptors has been shown to facilitate fear extinction, the behavioral consequences of 5-HT 2 AR antagonism during extinction is not well defined. Here, we examined the systemic effects of two 5-HT 2 A receptor antagonists, the mixed 5-HT 2 A/ 2 C...
British Journal of Pharmacology
July 1, 2026
Yuanyuan Wang, Yishan Yao, Ruibin Su et al.
1 citation
Fear-related psychiatric disorders such as phobias and anxiety are insufficiently treated by current therapies. Psychedelics targeting 5-HT₂A receptors show promise in modulating fear circuits, but their specific neurobiological substrates remain unclear. This study investigates the effects of 4-acetoxy-N,N-dimethyltryptamine (4-AcO-DMT), a psychedelic compound, on innate fear responses and...
Progress in Neuro-psychopharmacology and Biological Psychiatry
July 1, 2026
Guilherme Lodetti, Rafael Mariano de Bitencourt, Antonio Inserra et al.
BackgroundAlcohol use disorder (AUD) remains difficult to treat with lasting success, leading to growing interest in alternative therapeutic approaches. Psychedelic compounds such as Ayahuasca, a traditional brew used in Indigenous Amazonian ceremonies containing N,N-dimethyltryptamine (DMT) along with monoamine oxidase-inhibiting β-carbolines, have shown promise in reducing addictive...
Physical chemistry chemical physics : PCCP
July 1, 2026
W S Clemente Junior, K S Bezerra, E G C Matias et al.
Mental disorders represent a major global health problem, with depression being one of the most prevalent and disabling conditions worldwide. Growing evidence suggests that the serotonergic system, particularly the 5-HT2A receptor, plays an important role in modulating mood and cognitive processes, constituting a key pharmacological target for several psychoactive compounds. In this study, we...
Psychopharmacology
July 1, 2026
Sarah Ann Smith, Haseeb Mohammad, Lik Hang N Lee et al.
Interest in psychedelic drugs has increased rapidly because of their potential therapeutic role in psychiatric disorders. Impairments in the sociocognitive skills needed to build and maintain social relationships are prominent features of many psychiatric and neurodevelopmental disorders. Emerging evidence suggests that compounds such as 3,4-methylenedioxymethamphetamine (MDMA), lysergic acid...